A Phase 1 interventional study of Bicalutamide in Healthy, sponsored by Kremers Urban Development Company. Completed at 1 site in Canada. Open to male participants aged 19 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-03-02.
Sponsored by Kremers Urban Development Company · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablet (test) versus Casodex® (reference), administered as 1 x 50 mg tablet under fed conditions.
Kremers Urban Development Company is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bicalutamide 50 mg Tablet
Drug: Bicalutamide
Casodex® 50 mg Tablet
Drug: Bicalutamide
50 mg Oral Tablet
Also known as: Casodex®
AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose)
AUC0-144 (area under the concentration-time curve from time zero to 144 hour post-dose)
Time frame: 144 hour
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
maximum observed concentration of drug substance in plasma
Time frame: 144 hour
healthy subjects recruited in April 2005 by sfbc Anapharm at 2050, Boul. Rene-Levesque Quest, Saint-Foy, Quebec, Canada G1V 2K8
| Milestone | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 30 |
| Not completed | 0 | 0 |
AUC0-144 (area under the concentration-time curve from time zero to 144 hour post-dose)
| ng*h/mL | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet |
|---|---|---|
| AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose) | 114386.56 ± 14285.37 | 105377.55 ± 11989.86 |
maximum observed concentration of drug substance in plasma
| ng/mL | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet |
|---|---|---|
| Cmax (Maximum Observed Concentration of Drug Substance in Plasma) | 1253.60 ± 138.02 | 1134.86 ± 122.44 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bicalutamide 50 mg Tablet | — | — | 11/30 (36.7%) |
| Casodex® 50 mg Tablet | — | — | 18/30 (60%) |
| Event | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet |
|---|---|---|
| EcchymosisInjury, poisoning and procedural complications | 2/30 | 2/30 |
| Edema inject siteInjury, poisoning and procedural complications | 1/30 | 2/30 |
| Pain backMusculoskeletal and connective tissue disorders | 1/30 | 2/30 |
| Dry mouthGastrointestinal disorders | 0/30 | 1/30 |
| DyspepsiaGastrointestinal disorders | 0/30 | 1/30 |
| Pain abdomenGastrointestinal disorders | 1/30 | 1/30 |
| AstheniaGeneral disorders | 1/30 | 1/30 |
| PruritusGeneral disorders | 1/30 | 0/30 |
| Hysn inject siteInjury, poisoning and procedural complications | 0/30 | 1/30 |
| Cramp legMusculoskeletal and connective tissue disorders | 1/30 | 0/30 |
| Age, Categorical(Participants) | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 29 | 58 |
| >=65 years | 1 | 1 | 2 |
| Age Continuous(years) | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet | Total |
|---|---|---|---|
| Mean | 40.13 ± 14.10 | 37.93 ± 14.41 | 39.03 ± 14.18 |
| Sex: Female, Male(Participants) | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 30 | 30 | 60 |
| Region of Enrollment(participants) | Bicalutamide 50 mg Tablet | Casodex® 50 mg Tablet | Total |
|---|---|---|---|
| Canada | 30 | 30 | 60 |
The record gives a start of May 2005, a primary completion of Jul 2005 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bicalutamide
Kremers Urban Development Company